<b>日本人健康成人男性を対象としたフェンタニル1日用テープの麻薬拮抗薬非併用下における生物学的同等性試験 </b>

  • 木島 功嗣
    Meiji Seika ファルマ株式会社臨床開発推進部
  • 嶋田 顕
    昭和大学江東豊洲病院内科系診療センター内科(腫瘍内科)
  • 花田 隆造
    医療法人相生会墨田病院
  • 石渡 和也
    Meiji Seika ファルマ株式会社医薬研究所動態分析研究室
  • 森田 順
    Meiji Seika ファルマ株式会社臨床開発推進部

書誌事項

タイトル別名
  • <b>Bioequivalence Study of Fentanyl Tape for 1 Day without Use of Antinarcotic in Healthy Male Japanese Subjects </b>

説明

<p>FENTANYL Tape for 1 Day ⌈MEIJI⌋ is a generic drug of OneDuro® Patch (Janssen Pharmaceutical K.K.) under development by Meiji Seika Pharma Co., Ltd. and Yutoku Pharmaceutical Ind. Co., Ltd. The generic drug contains the same active ingredient fentanyl at the same dose in the same dosage form (transdermal absorption) as the original drug. In this study, 32 healthy male Japanese adults were recruited as subjects. Each subject applied a FENTANYL Tape for 1 Day 0.84 mg ⌈MEIJI⌋ and a OneDuro® Patch 0.84 mg once in a crossover manner, without concomitant use of antinarcotic. Bioequivalence of these drugs was investigated by analyzing pharmacokinetic parameters (Cmax and AUC0→t) as primary endpoints calculated from serum fentanyl concentration profiles in all 32 subjects. The results confirmed bioequivalence of the two products. Secondary endpoints including pharmacokinetic parameters such as AUC0→∞, MRTt and kel also supported bioequivalence of the two products. When a FENTANYL Tape for 1 Day 0.84 mg ⌈MEIJI⌋ or a OneDuro® Patch 0.84 mg was applied once for 24 hours without concomitant use of antinarcotic, there were no adverse events such as cutaneous reactions at the application site.</p>

収録刊行物

  • 臨床薬理

    臨床薬理 47 (4), 137-142, 2016

    一般社団法人 日本臨床薬理学会

参考文献 (2)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ